Concentrix Corporation (CNXC) Stock Price & Analysis
Concentrix Corporation (CNXC) closed at USD 34.25 on Thursday, October 22, 2026, up 13.77% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 30.11; the Oct 22, 2026 session ranged USD 30.28–34.59 on volume of 1,662,098 shares. Market capitalization is $2.09B, with a 52-week range of USD 19.12–48.08 (NMS). Source: Nexqual, retrieved October 23, 2026 at 07:56 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CNXC.md
Key facts (CNXC)
- Last four reported quarters (through Aug 31, 2026): revenue $9.97B, net income -$2.39B (-24.0% margin), free cash flow $575M (SEC filings).
- 2 of 80 tracked superinvestors hold CNXC (13F, Q2 2026): 0 new, 1 added, 1 reduced, 0 unchanged.
- Insider open-market sales, last ~7 months: 1 Form 4 filings, $134M; 1 not under a Rule 10b5-1 plan ($134M); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Insider open-market purchases, last ~7 months: 2 Form 4 filings, $91K; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 2.20 on a 1–5 scale) (5 analysts), mean target USD 32.6 (range 29–45).
- Total return with dividends: 1Y -24.6% vs S&P 500 +14.9%; 5Y -79.5% vs S&P 500 +80.3%.
- Next earnings: 2026-09-29, EPS estimate USD 2.92, revenue estimate $2.44B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (CNXC)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $5.59B | $6.32B | $7.11B | $9.62B | $9.83B | $9.97B |
| Gross profit | $1.97B | $2.26B | $2.58B | $3.45B | $3.44B | — |
| Operating income | $572M | $640M | $661M | $596M | -$918M | -$2.08B |
| Net income | $406M | $435M | $314M | $251M | -$1.28B | -$2.39B |
| EPS (diluted) | $7.70 | $8.28 | $5.70 | $3.71 | -$20.36 | — |
| Free cash flow | $365M | $461M | $497M | $429M | $572M | $575M |
| Gross margin | 35.3% | 35.7% | 36.2% | 35.9% | 35.0% | — |
| Operating margin | 10.2% | 10.1% | 9.3% | 6.2% | -9.3% | -20.9% |
| Net margin | 7.3% | 6.9% | 4.4% | 2.6% | -13.0% | -24.0% |
| Revenue growth | +18.4% | +13.2% | +12.5% | +35.2% | +2.2% | — |
| Cash + short-term investments | $182M | $145M | $295M | $241M | $327M | — |
| Total debt | $802M | $2.22B | $4.94B | $4.74B | $4.64B | — |
Fiscal years end Nov. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Aug 31, 2026) (CNXC)
P/S 0.2x · EV/Sales 0.6x · P/FCF 3.6x · P/B 1.2x · FCF yield 27.47% · Earnings yield -114.23% · Dividend yield (paid, TTM) 4.42% · Buyback yield (TTM) 4.74% · Net debt $4.13B · EV $6.22B
P/E at fiscal year-ends: Nov 2024 11.6x, Nov 2023 16.2x.
Superinvestors (SEC 13F-HR, Q2 2026) (CNXC)
2 of 80 tracked investors hold CNXC. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Richard Pzena | Pzena Investment Management | 0.22% | $76.5M | Added +16.0% |
| Tweedy Browne | 0.02% | $301K | Reduced -1.4% |
Insider sales (SEC Form 4, open-market, last ~7 months) (CNXC)
0 of 1 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-04-29 | Groupe Bruxelles Lambert | 6,000,000 | $134M | 68.4% | No | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Insider purchases (SEC Form 4, open-market, last ~7 months) (CNXC)
2 purchases, $91K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-07-08 | Caldwell Christopher A | President and CEO | 1,000 | $21K | 21.25 | Too little history (no open-market trades in 2023) |
| 2026-04-09 | Valentine Andre S | Chief Financial Officer | 2,500 | $70K | 27.95 | Too little history (no open-market trades in 2023–2025) |
Analysts (CNXC)
Consensus Buy (mean 2.20 on a 1–5 scale), 5 analysts; mean target USD 32.6 (low 29, high 45).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-30 | Canaccord Genuity | Maintained | Buy | $45 |
| 2026-06-30 | B of A Securities | Target lowered | Neutral | $32 → $26 |
| 2026-06-30 | Canaccord Genuity | Target lowered | Buy | $55 → $45 |
| 2026-06-30 | Barrington Research | Target lowered | Outperform | $38 → $30 |
| 2026-06-30 | Baird | Target lowered | Outperform | $40 → $30 |
Total return (dividends reinvested) (CNXC)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | -24.6% | -79.5% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -24.6% | -27.1% |
| Volatility (annualized) | 72.0% | 48.4% |
| Max drawdown | -54.6% (Oct 2025→Jul 2026) | -88.1% (Mar 2022→Jul 2026) |
CNXC revenue by region (fiscal year ended Nov 30, 2025)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| OTHERS | $5.06B | 51.5% | +6.2% |
| United States | $1.59B | 16.2% | -0.1% |
| Philippines | $1.13B | 11.5% | +6.8% |
| France | $1.05B | 10.7% | -5.3% |
| United Kingdom | $356.5M | 3.6% | -9.7% |
| Germany | $334.3M | 3.4% | -13.8% |
| Canada | $302.1M | 3.1% | -1.8% |
| Total revenue | $9.83B | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
CNXC suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Customer | IBM (IBM) | “•Selectively Pursue Strategic Acquisitions: We have made targeted acquisitions to increase our technology expertise, enter new verticals and geographies, and increase our scale, including our acquisitions of the IBM Customer Care Business, Convergys Corporation, PK, ServiceSource, Webhelp, and SAI Digital.” |
| Customer | Convergys | “•Selectively Pursue Strategic Acquisitions: We have made targeted acquisitions to increase our technology expertise, enter new verticals and geographies, and increase our scale, including our acquisitions of the IBM Customer Care Business, Convergys Corporation, PK, ServiceSource, Webhelp, and SAI Digital.” |
| Competitor | Accenture (ACN) | “Our major competitors include Accenture plc, Capgemini SE, Cognizant Technology Solutions Corporation, Endava UK Ltd., EPAM Systems, Inc., ExlService Holdings, Inc., Foundever Group, Genpact Limited, Globant S.A., HCL Technologies Limited, Infosys Limited, TaskUs Inc., Tata Consultancy Services, Teleperformance S.A., TELUS Digital, Thoughtworks Holding, Inc., and TTEC Holdings, Inc.” |
Quoted from the company's 10-K filed Jan 28, 2026.
Companies that name CNXC in their SEC reports
| Relationship to CNXC | Company | Filing | Sentence |
|---|---|---|---|
| supplier | Matinas BioPharma Holdings, Inc. (MTNB) | 10-K Mar 31, 2026 | “International, Inc., a publicly-traded customer journey experience company (NASDAQ: SREV) that was acquired in 2022 by Concentrix Corporation,” |
| supplier | TD SYNNEX CORP (SNX) | 10-K Jan 27, 2026 | “On December 1, 2020, the Company completed the previously announced separation of its customer experience services business (the "Separation"), in a tax-free transaction for federal income tax purposes, which was accomplished by the distribution of one hundred percent of the outstanding common stock of Concentrix Corporation ("Concentrix").” |
CNXC company outlook (results filed Sep 29, 2026)
- “Business Outlook: The following statements are based on the Company's current expectations for the fourth quarter and the full year fiscal 2026.”
- “The non-GAAP EPS guidance assumes no impact from changes in acquisition contingent consideration and foreign currency losses (gains), net included in other expense (income), net.”
- “Fourth Quarter Fiscal 2026 Expectations: • Fourth quarter reported revenue of $2.410 billion to $2.460 billion.”
- “Based on current exchange rates, these expectations assume an approximate 65-basis point negative impact of foreign exchange rates compared with the prior year period.”
Analysts expect $2.44B for the current quarter, in line with the midpoint of the company's guidance ($2.44B).
Quoted word-for-word from the SEC 8-K results press release.
CNXC analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Nov 2026) | $2.92 | $3.17 | -8.0% | $2.44B | 4 |
| Next quarter (ends Feb 2027) | $2.81 | $2.85 | -1.3% | $2.43B | 3 |
| Current fiscal year (ends Nov 2026) | $11.05 | $11.20 | -1.3% | $9.94B | 5 |
| Next fiscal year (ends Nov 2027) | $11.52 | $11.89 | -3.1% | $9.82B | 5 |
CNXC options: expected move
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 29 | 74.9% | ±17.3% |
| Dec 18, 2026 | 57 | 71.0% | ±22.8% |
| Jan 15, 2027 | 85 | 71.1% | ±27.7% |
| Apr 16, 2027 | 176 | 76.5% | ±42.0% |
30-day implied volatility 67.5% vs 78.4% realized over the last 30 trading days. Put/call ratio (volume) 0.38. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 07:56 UTC)
| Price | USD 34.25 |
|---|---|
| Change | ▲ 13.77% (up) |
| Previous Close | USD 30.11 |
| Open | USD 30.63 |
| Day Range | USD 30.28 – 34.59 |
| 52-Week Range | USD 19.12 – 48.08 |
| Volume | 1,662,098 shares |
| Market Cap | $2.09B |
| Exchange | NMS |
Technical Analysis (CNXC)
Nexqual's technical model rates CNXC "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 07:56 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 67.82 (neutral) |
| vs SMA50 | Above (USD 27.67) |
| MACD | 0.84 (positive) |
Analyst Ratings (CNXC)
Wall Street analysts rate CNXC "Buy" based on 5 analysts, with a mean price target of USD 32.6 (range USD 29–45), per Nexqual as of October 23, 2026 at 07:56 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 32.6 |
| High Target | USD 45 |
| Low Target | USD 29 |
| Buy / Hold / Sell | 3 / 2 / 0 |
Earnings (CNXC)
| Next Earnings Date | 2026-09-29 |
|---|---|
| EPS Estimate | USD 2.92 |
| Revenue Estimate | $2.44B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-08-31 | USD 2.92 vs est 2.7 ▲ beat |
| 2026-05-31 | USD 2.63 vs est 2.64 ▼ miss |
| 2026-02-28 | USD 2.61 vs est 2.65 ▼ miss |
| 2025-11-30 | USD 2.95 vs est 2.91 ▲ beat |
Source: Nexqual, October 23, 2026 at 07:56 UTC.
Financials & Fundamentals (CNXC)
| Total Revenue | $9.97B |
|---|---|
| Revenue Growth (latest quarter, YoY) | -1.20% |
| Gross Margin | +34.79% |
| Operating Margin | +7.18% |
| Profit Margin | -23.98% |
| ROE | -78.22% |
| Debt / Equity | 2.99 |
| Current Ratio | 1.23 |
| Total Cash | $244.69M |
| Total Debt | $5.28B |
| Free Cash Flow (last four quarters to Aug 2026, SEC 10-Q / 10-K) | $575.01M (5.8% of revenue) |
Source: Nexqual, October 23, 2026 at 07:56 UTC.
Financial Health Score (CNXC)
Nexqual rates Concentrix Corporation's overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 07:56 UTC.
| Growth | Mixed — Revenue +2.2% YoY (annual), slow |
|---|---|
| Profitability | Solid — Gross margin 35%, operating 7% (last 12 months) |
| Balance Sheet | Weak — $245M cash and investments vs $4.38B debt (Aug 2026, SEC) |
| Cash Flow | Solid — FCF $575M (last 4 quarters to Aug 2026, SEC), 6% margin |
| Efficiency | Critical — ROE -78%, ROA 3.5% |
Ownership (CNXC)
| Insider Ownership | +15.62% |
|---|---|
| Institutional Ownership | +113.69% |
| Shares Outstanding | 61.11M |
| Float | 47.21M |
| Short % of Float | +17.60% |
Source: Nexqual, October 23, 2026 at 07:56 UTC.
Leadership (CNXC)
Concentrix Corporation is led by Christopher A. Caldwell, President, CEO & Director, per Nexqual as of October 23, 2026 at 07:56 UTC.
| President, CEO & Director | Christopher A. Caldwell |
|---|---|
| Executive VP & CFO | Andre S. Valentine |
| Executive Vice President of Legal | Jane C. Fogarty |
| Executive Vice President of Global Sales & Account Management | Craig Gibson |
| Executive Vice President of Customer Success | Cormac J. Twomey |
Major Backers & Investors (CNXC)
Notable institutional backers of Concentrix Corporation include FMR, LLC, Pzena Investment Management LLC, AQR Capital Management, LLC, according to Nexqual as of October 23, 2026 at 07:56 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 9.35% |
| Pzena Investment Management LLC | 5.59% |
| AQR Capital Management, LLC | 5.35% |
| Kopernik Global Investors, Llc | 5.2% |
| UBS Group AG | 5.18% |
| Groupe Bruxelles Lambert S.A. | 4.54% |
| FIL LTD | 3.99% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 10.93% |
| Vanguard Group | 4.67% |
| Dimensional Fund Advisors | 4.3% |
Source: Nexqual, October 23, 2026 at 07:56 UTC.
From Concentrix Corporation's Latest SEC 10-K Filing (filed 2026-01-28)
Key Strengths & Strategy (as disclosed to the SEC)
- Beginning in fiscal year 2024, we increased our investment in technology to approximately 1% of revenue, including expenses related to the development of our iX suite of technology. •Corporate Culture Committed to Our Clients' Success: Our unified team allows us to deliver consistent and exceptional results.
- As our industry evolves, we will continue to invest in new technologies and faster growing markets to further sustain long-term growth. •Selectively Pursue Strategic Acquisitions: We have made targeted acquisitions to increase our technology expertise, enter new verticals and geographies, and increase our scale, including our acquisitions of the IBM Customer Care Business, Convergys Corporation, PK, ServiceSource, Webhelp, and SAI Digital.
- We design, build, and run fully integrated, end-to-end solutions — including customer experience ("CX") process optimization, technology innovation and design engineering, front- and back-office automation, analytics, and business transformation services — for clients in five primary industry verticals.
- Through our end-to-end capabilities, we believe we deliver better economic outcomes for our clients with solutions designed to meet their unique needs as they navigate a landscape characterized by discerning consumers and new market entrants.
Legal & Regulatory Risks (Item 1A, quoted)
- Our business is subject to many regulatory requirements, and changes in current regulations or their interpretation and enforcement, or the adoption of new regulations, could significantly increase our cost of doing business.
- Our results of operations could be adversely affected by litigation and other commitments and contingencies.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PONY | Pony AI Inc. | USD 5.02 | ▼ 0.4% |
| CHRN | ChronoScale Holdings Corporatio | USD 15.46 | ▼ 6.98% |
| DXC | DXC Technology Company | USD 16.08 | ▲ 4.42% |
| CSQR | Csquare, Inc. | USD 14.9 | ▼ 11.83% |
| PENG | Penguin Solutions, Inc. | USD 51.91 | ▼ 11.08% |
| KD | Kyndryl Holdings, Inc. | USD 15.2 | ▲ 5.92% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 07:56 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt